Exelixis (EX9) AI Stock Analysis

Exelixis

(Frankfurt:EX9)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

CABOMETYX franchise leadership and growthThe core cabozantinib franchise is expanding through both revenue growth and market-share gains across important oncology indications. Leading prescribing positions and rising prescription volume support durable commercial strength, while the established franchise provides a foundation for funding future pipeline development.

Negative Factors

Gross-to-net and margin pressureHigher gross-to-net deductions reduce the revenue retained from reported product sales and can pressure the economics of the commercial franchise. The sharp decline in TTM gross margin also indicates recent cost or mix pressure, which could limit how much revenue growth converts into durable earnings and cash flow.

Exelixis (EX9) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 17.44B
Dividend Yield: ―
Average Volume (3M): 216
Price to Earnings (P/E): 20.1
Beta (1Y): 0.40
Revenue Growth: 3.75%
EPS Growth: 34.23%
Country: Germany
Employees: 1,077
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Exelixis Business Overview & Revenue Model

Company Description

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available ther...

Exelixis Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 08, 2027

Earnings Call SentimentPositive

The call was strongly positive. Management reported solid revenue and CABOMETYX growth, improving market share in RCC and NET, robust zanzalintinib enrollment and broad pipeline expansion, while also highlighting a substantial potential CRC opportunity and continued share repurchases. The main challenges were sequentially higher operating expenses and taxes, a higher full-year gross-to-net estimate, volatile clinical-trial sales, and the previously reduced revenue guidance.

Positive Updates

Strong Third-Quarter Revenue and Profitability

Exelixis reported approximately $659 million in total revenue for the third quarter of 2026, including approximately $52 million in royalties from Ipsen and Takeda. GAAP net income was approximately $218 million, or $0.85 per diluted share, while non-GAAP net income was approximately $240 million, or $0.94 per diluted share.

Negative Updates

Operating Expenses Increased Sequentially

Total operating expenses increased to approximately $390 million in the third quarter of 2026 from $380 million in the second quarter. The increase was primarily driven by higher legal and advisory fees, marketing expenses and cost of goods sold, partially offset by lower license and other collaboration costs.

Company Guidance

Exelixis is now projecting full year 2026 gross-to-net deductions of approximately 30% and is updating full year 2026 financial guidance to reflect changes to cost of goods sold and tax rate estimates; it expects STELLAR-304 top line results in the first quarter next year, with the NDA based on STELLAR-303 having an updated PDUFA action date of March 3, 2027, plans to submit an IND for XL558 later this year, expects refill to continue to increase going forward in NET, and said its longer-term expectation is that the tax rate will be at the federal rate or thereabouts.

Exelixis Risk Analysis

Exelixis disclosed 31 risk factors in its most recent earnings report. Exelixis reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Exelixis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:EX9 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	71Outperform	$34.94B	45.64	13.58%	―	21.75%	-36.69%
INCY	68Neutral	$24.54B	57.33	7.11%	―	24.88%	-65.67%
JAZZ	65Neutral	$14.02B	14.21	21.37%	―	12.59%	―
SMMT	52Neutral	$12.82B	-14.31	-204.33%	―	―	-11.10%
ZLAB	52Neutral	$2.77B	-12.70	-27.40%	―	5.13%	17.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:EX9 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:EX9	Exelixis	58.79	25.69	77.61%
INCY	Incyte	120.39	18.82	18.53%
JAZZ	Jazz Pharmaceuticals	215.98	77.60	56.08%
SMMT	Summit Therapeutics PLC	16.03	-2.19	-12.02%
ZLAB	Zai Lab Ltd	22.07	-4.68	-17.50%
GMAB	Genmab (Otc)	57.06	28.35	98.75%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Exelixis AI Stock Analysis